Literature DB >> 11022774

Gingival fluid ciprofloxacin levels at healthy and inflamed human periodontal sites.

T B Conway1, F M Beck, J D Walters.   

Abstract

BACKGROUND: Polymorphonuclear leukocytes (PMNs) take up and accumulate ciprofloxacin. This may allow them to enhance the delivery of this agent to the inflamed periodontium.
METHODS: Cross-sectional and longitudinal approaches were used to test the hypothesis. In the cross-sectional study, 7 periodontally healthy adults and 8 adults with untreated periodontitis were administered three doses of ciprofloxacin (500 mg bid). Gingival fluid (GF) and serum samples were obtained after 28 hours and analyzed by high-performance liquid chromatography (HPLC). In the longitudinal study, 8 adult periodontitis subjects were administered 500 mg ciprofloxacin bid for 8 days. After 28 hours, GF from 4 sites with 5 to 8 mm probing depths was sampled in each subject, serum samples were obtained, and 2 of the 4 sites were root planed. GF and serum were sampled again 7 days later (196 hours after the initial dose).
RESULTS: The mean ciprofloxacin levels in the GF and serum of periodontally healthy subjects were 2.52 +/- 0.22 microg/ml and 0.47 +/- 0.05 microg/ml, respectively. In subjects with periodontitis, these levels were 2.69 +/- 0.44 microg/ml and 0.61 +/- 0.13 microg/ml, respectively. GF ciprofloxacin levels were significantly higher than corresponding serum levels in healthy and diseased subjects (P<0.01), but there were no significant differences in GF or serum levels between the 2 subject groups. Since GF flow was significantly higher at diseased sites, however, more ciprofloxacin was distributed to these sites than to healthy sites. In the longitudinal study, GF flow at 196 hours was 16% lower at root planed sites than at untreated control sites (P = 0.412). The minor decrease in this index of inflammation was accompanied by a small (9%), but statistically significant (P= 0.007), decrease in GF ciprofloxacin levels.
CONCLUSIONS: GF ciprofloxacin levels decreased slightly at inflamed periodontal sites after root planing, but were significantly higher than serum levels even at healthy periodontal sites. Inflammation may enhance the distribution of ciprofloxacin to diseased sites, but it is not a major determinant of GF ciprofloxacin levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11022774      PMCID: PMC2483303          DOI: 10.1902/jop.2000.71.9.1448

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  24 in total

1.  In vitro susceptibilities of Actinobacillus actinomycetemcomitans to a number of antimicrobial combinations.

Authors:  M J Pavicić; A J van Winkelhoff; J de Graaff
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  A simple high-performance liquid chromatographic assay for ciprofloxacin in human serum.

Authors:  L K Jim; N el-Sayed; K I al-Khamis
Journal:  J Clin Pharm Ther       Date:  1992-04       Impact factor: 2.512

3.  Quadratic calibration curves for the Periotron 6000.

Authors:  P M Preshaw; P J Kelly; P A Heasman
Journal:  J Periodontal Res       Date:  1996-08       Impact factor: 4.419

Review 4.  Systemic antibiotic therapy in periodontics.

Authors:  A J van Winkelhoff; T E Rams; J Slots
Journal:  Periodontol 2000       Date:  1996-02       Impact factor: 7.589

5.  Interactions of the oxygen-dependent antimicrobial system of the human neutrophil with difloxacin, ciprofloxacin, pefloxacin and fleroxacin in the intraphagocytic eradication of Staphylococcus aureus.

Authors:  C E van Rensburg; G Joone; R Anderson
Journal:  J Med Microbiol       Date:  1990-05       Impact factor: 2.472

6.  In vitro antimicrobial sensitivity of enteric rods and pseudomonads from advanced adult periodontitis.

Authors:  J Slots; D Feik; T E Rams
Journal:  Oral Microbiol Immunol       Date:  1990-10

Review 7.  Quinolone antimicrobial agents: mechanism of action and resistance development.

Authors:  L E Bryan; J Bedard; S Wong; S Chamberland
Journal:  Clin Invest Med       Date:  1989-02       Impact factor: 0.825

8.  Enterococci in human periodontitis.

Authors:  T E Rams; D Feik; V Young; B F Hammond; J Slots
Journal:  Oral Microbiol Immunol       Date:  1992-08

9.  Tissue localization of Actinobacillus actinomycetemcomitans in human periodontitis. I. Light, immunofluorescence and electron microscopic studies.

Authors:  L A Christersson; B Albini; J J Zambon; U M Wikesjö; R J Genco
Journal:  J Periodontol       Date:  1987-08       Impact factor: 6.993

10.  In vitro antimicrobial susceptibility of different serotypes of Actinobacillus actinomycetemcomitans.

Authors:  R Pajukanta; S Asikainen; M Saarela; S Alaluusua; H Jousimies-Somer
Journal:  Scand J Dent Res       Date:  1993-10
View more
  12 in total

1.  Effect of ciprofloxacin on killing of Actinobacillus actinomycetemcomitans by polymorphonuclear leukocytes.

Authors:  David A Cacchillo; John D Walters
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  Accumulation of ciprofloxacin and minocycline by cultured human gingival fibroblasts.

Authors:  Q Yang; R J Nakkula; J D Walters
Journal:  J Dent Res       Date:  2002-12       Impact factor: 6.116

3.  Effect of biologic mediators on ciprofloxacin accumulation by gingival fibroblasts.

Authors:  Swati Y Rawal; John D Walters
Journal:  J Periodontol       Date:  2005-12       Impact factor: 6.993

4.  Aggregatibacter actinomycetemcomitans biofilm killing by a targeted ciprofloxacin prodrug.

Authors:  Benjamin D Reeves; Mark Young; Paul A Grieco; Peter Suci
Journal:  Biofouling       Date:  2013-08-19       Impact factor: 3.209

5.  Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration.

Authors:  Pin-Chuang Lai; Weiting Ho; Nidhi Jain; John D Walters
Journal:  J Periodontol       Date:  2011-03-21       Impact factor: 6.993

6.  Distribution of systemic ciprofloxacin and doxycycline to gingiva and gingival crevicular fluid.

Authors:  Maria Lavda; C Esther Clausnitzer; John D Walters
Journal:  J Periodontol       Date:  2004-12       Impact factor: 6.993

7.  Azithromycin decreases crevicular fluid volume and mediator content.

Authors:  W Ho; T Eubank; B Leblebicioglu; C Marsh; J Walters
Journal:  J Dent Res       Date:  2010-04-16       Impact factor: 6.116

8.  Effect of gingivitis on azithromycin concentrations in gingival crevicular fluid.

Authors:  Nidhi Jain; Pin-Chuang Lai; John D Walters
Journal:  J Periodontol       Date:  2012-02-14       Impact factor: 6.993

9.  Comparison of Azithromycin and Amoxicillin Before Dental Implant Placement: An Exploratory Study of Bioavailability and Resolution of Postoperative Inflammation.

Authors:  Mariana Gil Escalante; Tim D Eubank; Binnaz Leblebicioglu; John D Walters
Journal:  J Periodontol       Date:  2015-08-07       Impact factor: 6.993

10.  Comparative Evaluation of Ciprofloxacin Levels in GCF and Plasma of Chronic Periodontitis Patients: Quasi Experimental Study.

Authors:  Madhavi Alamanda; Sunil Kumar Denthumdas; Umesh Wadgave; Pooja Mohan Pharne; Sandeep Jambukumar Patil; Sirisha Kondreddi; Pavan Deshpande; Rajesh Suresh Koppikar
Journal:  J Clin Diagn Res       Date:  2016-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.